Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 16, 2006 - Issue 10
Submit an article Journal homepage
41
Views
1
CrossRef citations to date
0
Altmetric
Editorial

Recent developments of small molecule endothelin modulators

Chengde Wu Encysive Pharmaceuticals, Inc. Research Laboratories, 7000 Fannin Street, Houston, TX 77030, USA. [email protected]
Pages 1337-1345 | Published online: 04 Oct 2006

Bibliography

  • YANAGISAWA M, KURIHARA H, KIMURA S et al.: Novel potent vasoconstrictor peptide produced by vascular endothelin cells. Nature (1988) 332:311-415.
  • INOUE A, YANAGISAWA M, KIMURA S et al.: The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. USA (1989) 86:2863-2867.
  • ARAI H, HORI S, ARAMORI I, OHKUBO H, NAKANISHI S: Cloning and expression of a cDNA encoding an endothelin receptor. Nature (1990) 348:730-732.
  • SAKURAI T, YANAGISAWA M, TAKUWA Y et al.: Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature (1990) 348:732-735.
  • SAKAMOTO A, YANAGISAWA M, SAKURAI T et al.: Cloning and functional expression of human cDNA for the ETB endothelin receptor. Biochem. Biophys. Res. Commun. (1991) 178:656-663.
  • HOSODA K, NAKAO K, ARAI H et al.: Cloning and expression of human endothelin-1 receptor cDNA. FEBS Lett. (1991) 187:23-26.
  • OGWA Y, NAKAO K, ARAI H et al.: Molecular cloning of a non-isopeptide selective human endothelin receptor. Biochem. Biophys. Res. Commun. (1992) 178:248-255.
  • STEWART D: Update on endothelin. Can. J. Cardiology (1998) 14(Suppl. D):11D-13D.
  • KRUM H, VISKOPER RJ, LACOURICERE Y, BUDDE M, CHARLEON V: The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N. Engl. J. Med. (1998) 338(12):784-790.
  • Myogen Press Release 18 August, 2005: Myogen reports positive results for darusentan Phase 2b trials in resistant hypertension.
  • SAKAI S, MIYAUCHI T, KOBAYASHI M et al.: Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature (1996) 384(6607):353-355.
  • MULDER P, RICHARD V, DERUMEAUX G et al.: Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation (1997) 96(6):1976-1982.
  • GIVERTZ MM, COLUCCI WS: New targets for heart-failure therapy: endothelin, inflammatory cytokines, and oxidative stress. Lancet (1998) 352(Suppl. I):S34-S38.
  • SCHIFFRIN EL, INTENGAN HD, THIBAULT G, TOUYZ RM: Clinical significance of endothelin in cardiovascular disease. Curr. Opin. Cardiol. (1997) 12(4):354-367.
  • WEBB DJ, STRACHAN FE: Clinical experience with endothelin antagonists. Am. J. Hypertension (1998) 11(4) Pt 3:71S-79S.
  • COLUCCI WS: Molecular and cellular mechanisms of myocardial failure. Am. J. Cardiol. (1997) 80(11A):15L-25L.
  • TAKAHASHI K, TOTSUNE K, MOURI T: Endothelin in chronic renal failure. Nephron (1994) 66:373-379.
  • COSENTINO F, KATUSIC ZS: Does endothelin-1 play a role in the pathogenesis of cerebral vasospasm? Stroke (1994) 25:904-908.
  • CLOZEL M, BREU V, BURRI K et al.: Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature (1993) 365:759-761.
  • NICCOLI G, LANZA GA, SHAW S et al.: Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularization. Eur. Heart J. (2006) 27:1793-1798.
  • WU C, CHAN MF, STAVROS F et al.: Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J. Med. Chem. (1997) 40(11):1690-1697.
  • TILTON RG, MUNSCH CL, SHERWOOD SJ et al.: Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ETA receptor antagonist. Pulmonary Pharmacol. Ther. (2000) 13:87-97.
  • GIVERTZ MM, COLUCCI WS, LEJEMTEL TH et al.: Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation (2000) 101(25):2922-2927.
  • BARST RJ, RICH S. WIDLITZ Z et al.: Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest (2002) 121:1860-1868.
  • BARST RJ, LANGLEBEN D, FROST A et al.: Sitxasentan, a selective ETA receptor antagonist, improves exercise capacity and NYHA functional class in pulmonary arterial hypertension (PAH). American Thoracic Society: 99th International Conference, 16 – 21 May, Seattle, Washington, USA (2003):Abstract B087.
  • FROST AE, LANGLEBEN D, OUDIZ R et al.: The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. Vasc. Pharmacol. (2005) 43(1):36-39.
  • BARST RJ, LANGLEBEN D, FROST A et al.: Sitxasentan, a selective ETA receptor antagonist, improves cardiopulmonary hemodynamics in pulmonary arterial hypertension (PAH). American Thoracic Society: 99th International Conference, 16 – 21 May, Seattle, Washington, USA (2003):Abstract A118.
  • BARST RJ: The STRIDE-2 trial: does selectivity matter in endothelin antagonism for PAH? Proc. Am. Thorac. Soc. (2005) 2(Abstracts Issue):A300.
  • GALIE N: STRIDE-2 trial: A placebo-controlled study for sitaxsentan in pulmonary arterial hypertension ESC Congress. 3 – 7 September, Stockholm, Sweden (2005):Abstract 761.
  • COYNE T, DIXON R: Sitaxsentan therapy in pulmonary arterial hypertension results in significantly fewer liver function abnormalities than bosentan. 69th Annual Science Meeting of the American College of Rheumatology. 12 – 17 November, San Diego, USA (2005):Abstract 367.
  • Encysive Pharmaceuticals Inc. Press Release 2006, Aug 11.
  • WU C, DECKER ER, BLOK N et al.: Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)-thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist. J. Med. Chem. (2004) 47(8):1969-1986.
  • RIECHERS H, ALBRECHT H-P, AMBERG W et al.: Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists. J. Med. Chem. (1996) 39(11):2123-2128.
  • BOLLI MH, MARFURT J, GRISOSTOMI C et al.: Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists. J. Med. Chem. (2004) 47(11):2776-2795.
  • RUBIN L, GALIE N, BADESCH D et al.: Ambrisentan improves exercise capacity and clinical measures in pulmonary arterial hypertension (PAH). Am. J. Respir. Crit. Care Med. (2004) 169(7, Suppl.):A210.
  • FROST A, MANES A, KEOGH A et al.: Ambrisentan improves 6-minute walk distance comparably for WHO class II and III PAH patients. Proc. Amer. Thorac. Soc. (2005) (Abstracts Issues): A198.
  • Myogen Press Release 2005, Dec 14.
  • Myogen Press Release 2006, April 12.
  • ROUX S, BREU V, GILLER T et al.: Ro 61-1790, a new hydrosoluble endothelin antagonists: general pharmacology and effects on experimental cerebral vasospasm. J. Pharmacol. Exp. Ther. (1997) 283 (3):1110-1118.
  • HORTOBAGYI T, GOERLACH C, BENVO M, WAHL M: In vitro characterization and in vivo action after brain trauma of a new endothelin receptor-A antagonists: RO 61-1790. Fundam. Clin. Pharmacol. (1999) 13(Suppl. 1):(Abstract) PS154.
  • VAJKOCZY P: Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter Phase IIa study. J. Neurosurg. (2005) 103(1):9.
  • WINN M, VON GELDERN TW, OPGENORTH TJ et al.: 2,4-Diarylpyrrolidine-3-carboxylic acids-potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722. J. Med. Chem. (1996) 39:1039-1048.
  • WENZEL RR: The ETA-selective antagonist SPP301 on top of standard treatment reduces urinary albumin excretion rate in patients with diabetic nephropathy. 38th Annual Meeting of the American Society of Nephrology (ASN). 8 – 13 November, Philadelphia, USA (2005):Abstract F-FC093.
  • CLOZEL M, BREY V, GRAY GA: Pharmacological characterization of bosentan, a new potent orally active non-peptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther. (1994) 270:228-235.
  • BLACK H: Darusentan antihypertensive effect in patients with resistant hypertension. J. Am. Coll. Cardiol. (2006) 47(4 Suppl. 1):Abstract 915-208.
  • HANESSIAN S, GAUCHET C, CHARRON G et al.: Design and synthesis of diversely substituted azacyclic inhibitors of endothelin converting enzyme. J. Org. Chem. (2006) 71(7):2760-2778.
  • Pharmacopeia Press Release. Pharmacopeia licenses novel therapeutic candidates from Bristol-Myers Squibb. 3 April, 2006.

Patents

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.